Immunocore
IMCR
26.41
-0.22
-0.83%
Immunocore
US · IMCR
#2968 by market cap
Listed 2021
26.41
-0.22
-0.83%
Periodic snapshot; not a real-time feed.
· 2026-11-20 16:10
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.0 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 100.98% -1.96pp
- Institutions
- 153 -6
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund48.95%
Hedge Fund47.64%
VC/PE Fund1.83%
Public Company1.17%
Private Company1.01%
Government Pension Fund0.38%
Individual/Insider0.10%
Other2.81%
Top holders as of 2026-06-30
Wellington Management Group
11.07% · 5.72M sh
RTW Investments, LP
9.42% · 4.87M sh
PRIMECAP Management Company
7.04% · 3.64M sh
Bellevue Asset Management AG
5.40% · 2.79M sh
Tang Capital Management, LLC
5.13% · 2.65M sh
Point72 Asset Management, L.P.
4.29% · 2.22M sh
Acadian Asset Management LLC
3.53% · 1.82M sh
Vestal Point Capital, LP
3.48% · 1.80M sh
FMR
3.36% · 1.74M sh
Millennium Management LLC
3.10% · 1.60M sh
Armistice Capital LLC
2.77% · 1.43M sh
Two Sigma Investments, LP
3.19% · 1.65M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 33 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Bahija Jallal | Chief Executive Officer | 0.05% |
| John Bell | Independent Non-Executive Chairperson | 0.03% |
| David Berman | Former Officer | 0.02% |
| Tina Leger | Former Chief Human Resources Officer | 0.00% |
| John Goll | SVP, Finance & Chief Accounting Officer | 0.00% |
| Peter Ratcliffe | Independent Non-Executive Director | 0.00% |
| Kristine Peterson | Independent Non-Executive Director | -- |
| Roy Steven Herbst | Independent Non-Executive Director | -- |
| Brian Di Donato | Former Executive VP, CFO & Strategy | -- |
| Baker Bros. Advisors LP | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-26 | John Bell | Independent Non-Executive Chairperson | Other Derivative Acquisition | +27,492 | $28.52 |
| 2026-05-26 | Kristine Peterson | Independent Non-Executive Director | Other Derivative Acquisition | +27,492 | $28.52 |
| 2026-05-26 | Roy Steven Herbst | Independent Non-Executive Director | Other Derivative Acquisition | +27,492 | $28.52 |
| 2026-05-26 | Peter Ratcliffe | Independent Non-Executive Director | Other Derivative Acquisition | +27,492 | $28.52 |
| 2026-05-26 | William Pao | Independent Non-Executive Director | Other Derivative Acquisition | +27,492 | $28.52 |
| 2026-05-26 | Siddharth Kaul | Independent Non-Executive Director | Other Derivative Acquisition | +27,492 | $28.52 |
| 2026-03-10 | David Berman | Former Officer | Intent to Sell (Form 144) | -11,832 | $32.57 |
| 2026-02-17 | Bahija Jallal | Chief Executive Officer | Derivative Exercise and Sale | -11,474 | $32.35 |
| 2026-02-17 | Bahija Jallal | Chief Executive Officer | Intent to Sell (Form 144) | -11,474 | $32.35 |
| 2026-02-17 | John Goll | SVP, Finance & Chief Accounting Officer | Derivative Exercise and Sale | -698 | $32.35 |
| 2026-02-17 | Tina Leger | Former Chief Human Resources Officer | Derivative Exercise and Sale | -1,000 | $32.35 |
| 2026-02-17 | Tina Leger | Former Chief Human Resources Officer | Intent to Sell (Form 144) | -1,000 | $32.35 |
| 2026-02-17 | David Berman | Former Officer | Derivative Exercise and Sale | -5,965 | $32.35 |
| 2026-02-17 | David Berman | Former Officer | Intent to Sell (Form 144) | -5,965 | $32.35 |
| 2026-02-16 | Bahija Jallal | Chief Executive Officer | Other Derivative Acquisition | +88,573 | -- |
| 2026-02-16 | Bahija Jallal | Chief Executive Officer | Other Derivative Acquisition | +395,066 | $32.38 |
| 2026-02-16 | Bahija Jallal | Chief Executive Officer | Derivative Exercise and Retained | +12,343 | -- |
| 2026-02-16 | John Goll | SVP, Finance & Chief Accounting Officer | Other Derivative Acquisition | +7,411 | -- |
| 2026-02-16 | John Goll | SVP, Finance & Chief Accounting Officer | Other Derivative Acquisition | +21,252 | $32.38 |
| 2026-02-16 | John Goll | SVP, Finance & Chief Accounting Officer | Derivative Exercise and Retained | +653 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.
Immunocore discussion 0 comments